Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Simard

Showing results (131-140 of 290) with videos related to

Pageof 29
Sort By:
Clinical Breast Cancer|February 5, 2026
Canadian Women's Attitudes Toward Receiving Personalized Breast Cancer Risk Information: Insights From the PERSPECTIVE I&I ProjectJennifer D Brooks, Kristina M Blackmore, Nguyet N M Ngo, et al.
NPJ Breast Cancer|May 13, 2021
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjectsNa Li, Magnus Zethoven, Simone McInerny, et al.
Breast Cancer Research : BCR|December 10, 2016
Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestryWanqing Wen, Xiao-Ou Shu, Xingyi Guo, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Cancers|June 2, 2021
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene StudyJulie Lapointe, Michel Dorval, Jocelyne Chiquette, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
European Journal of Human Genetics : EJHG|February 16, 2026
Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service modelsOuerdia Haroun, Julie Lapointe, Rachel Guérard, et al.
Pageof 29

Showing results (131-140 of 290) with videos related to

Sort By:
Pageof 29
Clinical Breast Cancer|February 5, 2026
Canadian Women's Attitudes Toward Receiving Personalized Breast Cancer Risk Information: Insights From the PERSPECTIVE I&I ProjectJennifer D Brooks, Kristina M Blackmore, Nguyet N M Ngo, et al.
NPJ Breast Cancer|May 13, 2021
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjectsNa Li, Magnus Zethoven, Simone McInerny, et al.
Breast Cancer Research : BCR|December 10, 2016
Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestryWanqing Wen, Xiao-Ou Shu, Xingyi Guo, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Cancers|June 2, 2021
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene StudyJulie Lapointe, Michel Dorval, Jocelyne Chiquette, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
European Journal of Human Genetics : EJHG|February 16, 2026
Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service modelsOuerdia Haroun, Julie Lapointe, Rachel Guérard, et al.
Pageof 29